5 Drugs Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 16,096 as of Monday, Nov. 25, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,434 issues advancing vs. 1,496 declining with 119 unchanged.

The Drugs industry currently sits up 1.1% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Cubist Pharmaceuticals ( CBST), up 8.5%, Biogen Idec ( BIIB), up 4.2%, Vertex Pharmaceuticals ( VRTX), up 3.1%, Amgen ( AMGN), up 0.7% and Eli Lilly and Company ( LLY), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Celgene Corporation ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene Corporation is up $2.05 (1.2%) to $165.38 on average volume. Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $163.44-$165.74 after having opened the day at $164.73 as compared to the previous trading day's close of $163.33.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $65.4 billion and is part of the health care sector. The company has a P/E ratio of 45.6, above the S&P 500 P/E ratio of 17.7. Shares are up 102.1% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Gilead ( GILD) is up $0.72 (1.0%) to $74.99 on average volume. Thus far, 4.9 million shares of Gilead exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $74.60-$75.43 after having opened the day at $75.42 as compared to the previous trading day's close of $74.27.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $109.8 billion and is part of the health care sector. The company has a P/E ratio of 39.4, above the S&P 500 P/E ratio of 17.7. Shares are up 95.0% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Merck ( MRK) is up $0.40 (0.8%) to $49.34 on light volume. Thus far, 4.3 million shares of Merck exchanged hands as compared to its average daily volume of 14.0 million shares. The stock has ranged in price between $48.94-$49.41 after having opened the day at $48.95 as compared to the previous trading day's close of $48.94.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $142.1 billion and is part of the health care sector. The company has a P/E ratio of 32.6, above the S&P 500 P/E ratio of 17.7. Shares are up 19.5% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.55 (0.6%) to $95.80 on light volume. Thus far, 2.1 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.5 million shares. The stock has ranged in price between $95.08-$95.87 after having opened the day at $95.49 as compared to the previous trading day's close of $95.25.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $268.6 billion and is part of the health care sector. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. Shares are up 35.9% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.34 (1.1%) to $32.46 on light volume. Thus far, 8.1 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.7 million shares. The stock has ranged in price between $32.10-$32.50 after having opened the day at $32.12 as compared to the previous trading day's close of $32.12.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $207.2 billion and is part of the health care sector. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. Shares are up 28.1% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Stocks Trade Mixed, Energy Shares Fall on Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Drop in Oil Prices

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves